Skip to main content
Shyamasundaran Kottilil, MD, Infectious Disease, Baltimore, MD

ShyamasundaranKottililMDPhD, MACP, FRCP, FIDSA, FAASLD

Infectious Disease Baltimore, MD

Director

Dr. Kottilil is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kottilil's full profile

Already have an account?

  • Office

    725 W Lombard St
    Baltimore, MD 21201
    Phone+1 410-328-9102
    Fax+1 410-706-4619

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2000 - 2002
  • Brown University
    Brown UniversityResidency, Internal Medicine, 1997 - 2000
  • Government Medical College Thrissur
    Government Medical College ThrissurClass of 1991

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2014 - 2026
  • DC State Medical License
    DC State Medical License 2009 - 2024
  • VA State Medical License
    VA State Medical License 2001 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients with Unfavorable Treatment CharacteristicsA Randomized Clinical Trial
    Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients with Unfavorable Treatment CharacteristicsA Randomized Clinical TrialSeptember 19th, 2019
  • UM School of Medicine Awarded Nearly $30 Million to Improve Health Outcomes of IV Drug Users
    UM School of Medicine Awarded Nearly $30 Million to Improve Health Outcomes of IV Drug UsersDecember 13th, 2023
  • UM School of Medicine Awarded Nearly $30 Million to Prevent Infections Associated with IV Drug Use
    UM School of Medicine Awarded Nearly $30 Million to Prevent Infections Associated with IV Drug UseDecember 21st, 2023

Grant Support

  • Therapeutic Strategies For The Management Of HCV/HIV CO-National Institute Of Allergy And Infectious Diseases2006
  • Role Of Innate Immunity In The Initiation And PathogenesNational Institute Of Allergy And Infectious Diseases2006

Professional Memberships